Zeng Chunyu, Han Yu, Huang Hefei, Yu Changqing, Ren Hongmei, Shi Weibin, He Duofen, Huang Lan, Yang Chengming, Wang Xukai, Zhou Lin, Jose Pedro A
Department of Cardiology, Daping Hospital, Chongqing, PR China.
J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b.
Vascular smooth muscle cell (VSMC) proliferation is central to the development of vascular diseases, including hypertension, which is regulated by numerous hormones and humoral factors. Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the D3 dopamine receptor, a member of the D2-like receptor family. Insulin is a proliferative hormone but it is not known if there is any interaction between insulin and D1-like receptors. We hypothesized that Dl-like receptors may have an inhibitory effect on the insulin-induced VSMC proliferation; aberrant insulin and Dl-like receptor functions could be involved in the pathogenesis of essential hypertension.
VSMC proliferation was determined by [H]-thymidine incorporation; insulin receptor mRNA and protein expressions were determined by RT-PCR, immunoblotting, and immunohistochemistry.
Insulin increased VSMC proliferation in immortalized aortic A10 cells, determined by [H]-thymidine incorporation. Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam, a D1-like receptor agonist, inhibited the stimulatory effect of insulin. The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist. Fenoldopam also inhibited insulin receptor mRNA and protein expression, which was time dependent and concentration dependent. A PKC or MAP kinase inhibitor blocked the inhibitory effect of fenoldopam on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway.
The inhibitory effect of D1-like receptors on insulin-mediated VSMC proliferation may play an important role in the regulation of blood pressure.
血管平滑肌细胞(VSMC)增殖是包括高血压在内的血管疾病发展的核心,其受多种激素和体液因子调节。我们之前的研究表明,去甲肾上腺素对VSMC增殖的刺激作用受到D1样受体和D2样受体家族成员D3多巴胺受体的抑制。胰岛素是一种促增殖激素,但尚不清楚胰岛素与D1样受体之间是否存在相互作用。我们假设D1样受体可能对胰岛素诱导的VSMC增殖具有抑制作用;胰岛素和D1样受体功能异常可能参与原发性高血压的发病机制。
通过[H] - 胸腺嘧啶核苷掺入法测定VSMC增殖;通过逆转录聚合酶链反应(RT-PCR)、免疫印迹和免疫组织化学法测定胰岛素受体mRNA和蛋白表达。
通过[H] - 胸腺嘧啶核苷掺入法测定,胰岛素增加了永生化主动脉A10细胞中的VSMC增殖。尽管D1样受体本身对VSMC增殖没有影响,但D1样受体激动剂非诺多泮刺激可抑制胰岛素的刺激作用。非诺多泮对胰岛素介导的VSMC增殖的抑制作用具有受体特异性,因为其作用可被D1样受体拮抗剂SCH23390阻断。非诺多泮还抑制胰岛素受体mRNA和蛋白表达,且具有时间依赖性和浓度依赖性。蛋白激酶C(PKC)或丝裂原活化蛋白激酶(MAP激酶)抑制剂可阻断非诺多泮对胰岛素受体表达的抑制作用,表明PKC和MAP激酶参与了信号通路。
D1样受体对胰岛素介导的VSMC增殖的抑制作用可能在血压调节中起重要作用。